Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Growth in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 15th total of 2,100,000 shares. Based on an average trading volume of 875,000 shares, the short-interest ratio is presently 2.5 days. Approximately 2.6% of the company’s stock are sold short.

Compass Therapeutics Trading Up 4.0 %

CMPX stock opened at $2.60 on Tuesday. The stock has a market cap of $357.73 million, a P/E ratio of -7.03 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.76 and a twelve month high of $2.70. The company’s 50 day moving average is $1.64 and its two-hundred day moving average is $1.51.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, equities research analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

A number of large investors have recently made changes to their positions in the company. Barclays PLC increased its position in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares during the period. Geode Capital Management LLC increased its holdings in shares of Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after acquiring an additional 19,095 shares during the period. Renaissance Technologies LLC raised its position in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the last quarter. Rhumbline Advisers boosted its stake in Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after purchasing an additional 12,315 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Compass Therapeutics during the 3rd quarter worth $79,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CMPX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $5.00 to $4.00 in a report on Friday, November 15th. Finally, Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.80.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.